Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100707 50 µg 30€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100708 200 µg 86€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  2. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  3. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  4. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  5. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  6. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  7. Zveik O, et al. 2022. Glia. 70:1191. PubMed
  8. Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed
  9. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  10. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  11. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  12. Zheng D, et al. 2023. Bioact Mater. 22:567. PubMed
  13. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  14. He Y, et al. 2022. Front Immunol. 13:986202. PubMed
  15. Hao J, et al. 2022. Cell Rep. 41:111804. PubMed
  16. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  17. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  18. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  19. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  20. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  21. Glaubitz J, et al. 2023. Gut. :. PubMed
  22. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  23. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  24. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  25. Pan C, et al. 2022. Cell Mol Immunol. 19:516. PubMed
  26. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  27. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  28. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  29. He Y, et al. 2022. Adv Healthc Mater. 11:e2200905. PubMed
  30. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  31. Shi X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2208506119. PubMed
  32. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  33. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  34. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  35. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  36. Wang F, et al. 2023. Int J Mol Sci. 24:. PubMed
  37. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  38. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  39. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  40. Dang YZ, et al. 2023. Neoplasma. 70:123. PubMed
  41. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  42. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
  43. Tao Q, et al. 2023. Microbiol Spectr. :e0522922. PubMed
  44. Fukuzaki Y, et al. 2023. iScience. 26:106340. PubMed
  45. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  46. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  47. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  48. Qin T, et al. 2023. Virol J. 20:75. PubMed
  49. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  50. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
  51. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
  52. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  53. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  54. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  55. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  56. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  57. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  58. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  59. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  60. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  61. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  62. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  63. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  64. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  65. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  66. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  67. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  68. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  69. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  70. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  71. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  72. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  73. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  74. Diao L, et al. 2022. iScience. 25:105511. PubMed
  75. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  76. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  77. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  78. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  79. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  80. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  81. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  82. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  83. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  84. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  85. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  86. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  87. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  88. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  89. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  90. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  91. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  92. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  93. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  94. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  95. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  96. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  97. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  98. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  99. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  100. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  101. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  102. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  103. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  104. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  105. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  106. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  107. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  108. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  109. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  110. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  111. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  112. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  113. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  114. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  115. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  116. Li J, et al. 2019. JCI Insight. 5. PubMed
  117. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  118. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  119. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  120. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  121. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  122. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  123. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  124. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  125. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  126. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  127. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  128. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  129. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  130. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  131. Yang H, et al. 2022. Nutrients. 14:. PubMed
  132. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  133. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  134. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  135. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  136. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  137. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  138. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  139. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  140. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  141. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  142. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  143. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  144. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  145. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  146. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  147. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  148. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  149. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  150. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  151. Cho K, et al. 2021. iScience. 24:103117. PubMed
  152. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  153. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  154. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  155. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  156. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  157. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  158. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  159. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  160. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  161. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  162. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  163. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  164. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  165. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  166. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  167. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  168. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  169. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  170. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  171. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  172. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  173. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  174. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  175. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  176. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  177. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  178. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  179. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  180. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  181. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  182. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  183. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  184. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  185. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  186. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  187. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  188. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  189. Li J, et al. 2020. Development. :. PubMed
  190. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  191. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  192. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  193. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  194. Zhang J, et al. 2018. Nature. 553:91. PubMed
  195. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  196. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  197. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  198. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  199. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  200. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  201. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  202. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  203. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  204. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  205. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  206. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  207. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  208. Koide S, et al. 2022. iScience. 25:103603. PubMed
  209. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  210. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  211. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  212. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  213. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  214. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  215. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  216. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  217. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  218. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  219. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  220. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  221. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  222. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  223. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  224. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  225. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  226. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  227. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  228. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  229. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  230. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  231. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  232. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  233. Chavez JS, et al. 2022. Cells. 11:. PubMed
  234. Wang X, et al. 2022. Elife. 11:. PubMed
  235. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  236. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  237. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  238. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  239. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  240. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  241. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  242. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  243. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  244. Zeng A, et al. 2020. Oncol Rep. . PubMed
  245. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  246. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  247. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  248. Gawish R, et al. 2022. Elife. 11:. PubMed
  249. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  250. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  251. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  252. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  253. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  254. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  255. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  256. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  257. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
RRID
AB_312747 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account